Mariner
IOVA icon

Mariner’s Iovance Biotherapeutics IOVA Stock Holding History

Mariner’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$401K Buy
+114,292
New +$366K ﹤0.01% 2652
2025
Q4 		– Sell
-22,291
Closed -$48.4K – 3671
2025
Q3 		$48.4K Buy
+22,291
New +$52.6K ﹤0.01% 3451
2025
Q2 		– Sell
-15,922
Closed -$53K – 3574
2025
Q1 		$53K Sell
15,922
-111
-0.7% -$572 ﹤0.01% 3306
2024
Q4 		$119K Sell
16,033
-2,483
-13% -$23K ﹤0.01% 3144
2024
Q3 		$174K Sell
18,516
-866
-4% -$8.21K ﹤0.01% 2968
2024
Q2 		$155K Buy
19,382
+2,722
+16% +$29.2K ﹤0.01% 2851
2024
Q1 		$247K Buy
16,660
+287
+2% +$3.34K ﹤0.01% 2599
2023
Q4 		$133K Sell
16,373
-355,477
-96% -$1.86M ﹤0.01% 2799
2023
Q3 		$1.69M Buy
371,850
+192,450
+107% +$1.26M ﹤0.01% 1049
2023
Q2 		$1.26M Buy
179,400
+72,100
+67% +$516K ﹤0.01% 1173
2023
Q1 		$656K Buy
107,300
+44,600
+71% +$308K ﹤0.01% 1530
2022
Q4 		$401K Buy
+62,700
New +$490K ﹤0.01% 1804

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Mariner's IOVA Position: Q1 2026 in Review

Mariner opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 114,292 shares worth $401K. The stake represents ﹤0.01% of the portfolio and ranks #2652 among its holdings. This is a return to the name: Mariner previously reported a position in IOVA as recently as Q3 2025.

Mariner first reported a position in IOVA in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.69M in Q3 2023. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Mariner held 114,292 shares of Iovance Biotherapeutics worth $401K as of Q1 2026.
  • Iovance Biotherapeutics was a new Mariner position in Q1 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2652 holding.
  • Mariner first reported a position in Iovance Biotherapeutics in Q4 2022 and has held it in 12 quarters since.
  • Mariner's Iovance Biotherapeutics position peaked at $1.69M in Q3 2023.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.